Diversity in Clinical Trials

Diversity in Clinical Trials – How to stop talking about it and actually do it

Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…

Pharmacists in clinical trials

Moving the Needle: How the Practice of Pharmacy Addresses Key Issues in Clinical Research

Pharmacists demonstrate tremendous expertise in drug counseling and dispensation, so it seems undeniable that they should play a prominent role in clinical research. After all, clinical trials are designed to establish the safety and efficacy of drugs: a pharmacist’s specialty. However, pharmacists are rarely consulted in clinical trials. To remedy this issue, Founder and CEO…

RxE2 Founder and CEO Gerald Finken on the Role and Value of Pharmacists in Clinical Research

Pharmacists demonstrate tremendous expertise in drug counseling and dispensation, so it seems undeniable that they should play a prominent role in clinical research. Surprisingly, their skill sets are rarely used in clinical trials. That’s why Founder and CEO Gerald Finken created RxE2, a community-based decentralized trial technology company spearheaded by pharmacists, offering primary stakeholders their…

E2 Dispensing Webinar

Welcome to our E2 Dispensing Webinar series. Over the next few weeks, we will release 8 episodes, introducing the E2 dispensing methodology and ecosystem to all. These webinars are aimed at everyone involved in clinical research and clinical trials. We will go into RxE2’s innovative and disruptive way of simplifying decentralized clinical trials and more specifically introducing…

How to boost excellence and innovation in clinical supply chains

By: Gerald E. Finken Originally posted on Linkedin In November 2021, McKinsey & Company published an interesting article on how to boost excellence and innovation in clinical supply chains that are relevant to today’s industry practices. What I found most compelling was how a best-in-class clinical supply chain could change and adapt to accommodate decentralized clinical trials (DCTs)…

The Impact of Decentralized Clinical Trials on the Investigational Drug Supply Chain: Making Clinical Supplies Patient-Centric

By: Gerald E. Finken The introduction of decentralized clinical trials (“DCTs”) into clinical research has, in recent years, focused on the use of technology and telehealth to improve the clinical trial experience for patients. The proponents of the DCT model have heralded it, and rightly so, with improving study recruitment, providing better patient diversity, and…